Chemoprevention in Barrett's oesophagus.
Increasing incidence of oesophageal adenocarcinoma along with poor survival entails novel preventive strategies. Agents that target pro-oncogenic pathways in Barrett's mucosa could halt this neoplastic transformation. In this review, we will use epidemiological associations and molecular mechanisms to identify novel chemoprevention targets in Barrett's oesophagus. We will also discuss recent chemoprevention trials.
Mayo Clinic College of Medicine, Department of Gastroenterology and Hepatology, Rochester, MN, USA.
Anushka
A
Baruah
Mayo Clinic College of Medicine, Department of Gastroenterology and Hepatology, Rochester, MN, USA. Electronic address: buttar.navtej@mayo.edu.
Navtej S
NS
Buttar
D000230:Adenocarcinoma / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D001471:Barrett Esophagus / Q000150:complications / Q000188:drug therapy*; D018890:Chemoprevention / Q000379:methods*; D004938:Esophageal Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D015994:Incidence
Barrett's oesophagus(BO); Chemo-preventive agents; Oesophageal adenocarcinoma(OAC); Surrogate endpoint markers(SEBs)